John Kerr posted in cancer • chemotherapy • health economics • pharmac • pharmaceuticals on December 4th, 2015.
Experts are calling for greater transparency and fairness in cancer drug pricing, in light of findings revealing discrepancies between Europe, Australia and New Zealand. The results come from a new study published today in the journal Lancet Oncology. The researchers, including a New Zealander, looked at the costs of more than 30 drugs and found […]
Continue reading “Transparency needed in cancer drug markets – Expert reaction”